I
Isomorphic Labs
An artificial intelligence company to discover new drugs
About Isomorphic Labs
Isomorphic Labs, founded in 2021, is an AI-driven company dedicated to revolutionizing drug discovery and development. By leveraging the groundbreaking advancements from Google DeepMind, such as AlphaFold, Isomorphic Labs aims to apply machine learning and computational methods to tackle complex biological challenges. The company operates at the intersection of AI, biotechnology, and medicine, focusing on developing predictive and generative models to enhance the efficiency and effectiveness of drug design and medical research.
Read full description
Supported by the robust infrastructure of Alphabet Inc., Isomorphic Labs combines the agility of a startup with substantial resources and expertise. The leadership team, including notable figures like Sir Demis Hassabis and Colin Murdoch, drives the company's mission to transform how medicine is discovered and delivered. Their approach integrates deep learning, reinforcement learning, and other advanced AI techniques to innovate within the life sciences, aiming to bring better therapeutic solutions to market more swiftly and accurately.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- 408
- Open positions
- 17
- Dealroom signal
- 96.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Verified Unicorns and $1B Exits, Tech for Biotech and Pharma, AI Drug Discovery, BIA Techbio UK
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
News
Google DeepMind resets leadership: Hassabis becomes chair, Kavukcuoglu takes operational lead
Aug 13, 2026
News
GSK bets $110M on Relation's biological data — not its AI model
Jul 30, 2026
News
Demis Hassabis: A Framework for Frontier AI and the Dawning of a New Age
Jul 14, 2026
Market map
Computational Biology & Chemistry startups in Europe
Market map
UK Techbio landscape
Market map
Deep Tech flywheel in Europe
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B | May 2026 | $2.1B | $8.4B | GV · MGX · CapitalG · Alphabet | Google | ↗ |
| LATE VC | Mar 2025 | $600M | $2.4B | GV · Thrive Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Isomorphic Labs is 130K monthly website visits, up 38.3% over the last three months. Isomorphic Labs's team grew 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
MGX
CapitalG
Alphabet | Google
UK Sovereign AI
Temasek
Series B and later3 investors entered at this stage
Google DeepMind
Thrive Capital
GV
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Isomorphic Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Isomorphic Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.